Atypical antipsychotic double patients' risk of dying from sudden heart failure, a study has found. It's the latest in a succession of reports contradicting the long-held assumption that the new drugs--which include Johnson & Johnson's Risperdal, Eli Lilly's Zyprexa and AstraZeneca's Seroquel--are safer than the older and much less expensive medications that they replaced. Report